表紙
市場調査レポート

ジェネリック医薬品の世界市場

Global Markets for Generic Drugs

発行 BCC Research 商品コード 210210
出版日 ページ情報 英文 197 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
ジェネリック医薬品の世界市場 Global Markets for Generic Drugs
出版日: 2014年02月03日 ページ情報: 英文 197 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2012年における世界のジェネリック医薬品市場は2,698億米ドルに達しました。同市場額は今後11.5%のCAGRで拡大し、2013年に3,009億米ドル、2018年に5,185億米ドルに達すると予測されています。

当レポートでは、世界のジェネリック医薬品市場の動向と2016年までの予測、参入企業による戦略、業界構造、主要なジェネリック薬メーカーのプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

  • 市場規模と発展

第3章 概要

  • ジェネリック医薬品部門の近年の歴史

第4章 新しいジェネリック医薬品の時代

  • 特許失効
  • ジェネリック医薬品の種類

第5章 主なジェネリック医薬品の問題

  • 規制環境
  • EU
  • 日本
  • バイオシミラーの規制
  • 「大手製薬企業」による守備的戦略
  • 「認可ジェネリック医薬品」
  • ユーザーの料金
  • ジェネリック医薬品の変化する環境
  • 欧州における状況
  • 特許・IP
  • 追加保護証明書(SPC)

第6章 ジェネリック医薬品市場

  • 世界の医薬品・ジェネリック医薬品市場
  • 市場機会:製品クラス別

第7章 世界のジェネリック医薬品産業

  • 動向
  • ジェネリック医薬品産業の構造
  • 近年のM&A活動

第8章 ジェネリック医薬品企業トップ10社のプロファイル

第9章 その他の国際的ジェネリック医薬品企業

第10章 南北アメリカ地域

  • 米国
  • カナダ
  • ラテンアメリカ
  • メキシコ

第11章 アジア地域

  • 日本
  • インド
  • 中国

第12章 欧州市場

  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ロシア

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM009G

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

This report provides:

  • An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
  • Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
  • Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and a considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.

REASONS FOR DOING THE STUDY

  • This is a time of growth and change for the generic pharmaceutical sector. Major aspects that combine to create an opportunity for an up-to date market analysis include the following:
  • The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time fierce price competition in this area has put some companies in difficulties because of slashed profit margins. The main result has been a wave of M&A activity, and the rise of “supergenerics” offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
  • A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition - the phenomenon widely known as the “patent cliff.” But the originator companies are deploying formidable strategies to protect their franchise, including marketing their own branded generics.
  • With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field - biogenerics, or biosimilars - is opening up for those generics companies capable of (or prepared to buy in) the technological expertise required.
  • The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico and Brazil are among rising centers of generic activity.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20-plus generics companies, and an update on mergers and acquisitions (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected on the basis of 2011-dollar value without attempting to predict the effect of inflation/deflation.

Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g. hypolipidaemics and antihypertensives) and drugs for respiratory conditions including asthma and COPD.

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of two previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • MARKET SIZE AND EVOLUTION
  • SUMMARY TABLE: MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 ($ BILLIONS)
  • SUMMARY FIGURE: MAJOR NATIONAL GENERIC MARKETS, 2012-2018 ($ BILLIONS)

CHAPTER 3 - OVERVIEW

  • TABLE 1: GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION, THROUGH 2018 ($ BILLIONS)
  • RECENT HISTORY OF THE GENERICS SECTOR
    • ROCHE-BOLAR
    • GENERICS LOBBY
    • ICH

CHAPTER 4 - THE NEW GENERICS ERA

  • THE PATENT CLIFF
    • TABLE 2: MAJOR PATENT EXPIRATIONS IN 2011 AND 2012
    • TABLE 3: MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE EXPIRIES
    • TABLE 4: BRAND SALES BEFORE AND AFTER PATENT EXPIRY ($ BILLIONS)
  • TYPES OF GENERICS
    • ‘SIMPLE' GENERICS
      • Adequate Market Size
      • Patent-expired Therapies
      • Older Products Still Used
      • Long-term Use
      • Straightforward Production Technology
      • Drugs Used in Primary Care
    • SUPERGENERICS
    • BIOSIMILARS
      • TABLE 5: BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN 2013 (SALES IN U.S. DOLLARS FOR Q1 2013)
      • TABLE 6: BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006
      • TABLE 7: EU APPROVED BIOSIMILAR APPLICATIONS, 2012
      • Special Challenges
      • The Biosimilar Market
      • Some Biosimilar Developments and Introductions
        • EPO
        • G-CSF
        • Interferons
        • hGH
        • Monoclonal Antibodies

CHAPTER 5 - MAJOR GENERIC ISSUES

  • REGULATORY ENVIRONMENT
    • U.S.
      • TABLE 8: REQUIREMENTS FOR NDA AND ANDA APPLICATIONS
  • EUROPEAN UNION
    • EU Marketing Authorization Systems
    • The Centralized Procedure
    • Decentralized and Mutual Recognition Procedures
    • Mutual Recognition Procedure
    • Types of Application
      • Applications under Article 10 (Generic Products)
  • JAPAN
    • Approval (Shonin) of Pharmaceuticals
  • REGULATION OF BIOSIMILARS
    • EU Provisions
    • Evolving Situation in the U.S.
      • User Fees
      • Hatch-Waxman and Bolar
  • DEFENSIVE STRATEGIES BY 'BIG PHARMA'
  • "AUTHORIZED GENERICS"
  • USER FEES
  • A CHANGING CLIMATE FOR GENERICS
  • THE SITUATION IN EUROPE
  • PATENTS AND I.P.
  • SUPPLEMENTARY PROTECTION CERTIFICATES (SPCS)

CHAPTER 6 - THE GENERIC MARKET

  • GLOBAL PHARMACEUTICAL AND GENERICS MARKET
    • GLOBAL GENERIC MARKET
    • MAIN NATIONAL GENERICS MARKETS
      • TABLE 9: WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS)
      • TABLE 10: CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2018 ($ BILLIONS)
  • MARKET OPPORTUNITIES BY PRODUCT CLASS
    • LEADING GENERIC MOLECULES
      • TABLE 11: TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 ($ BILLIONS)
    • Anti-infectives
      • TABLE 12: LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013.
    • Central Nervous System Therapies
      • Antidepressants
      • Antipsychotics
        • TABLE 13: LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013
    • Anxiolytics
      • Sleep Disorders
      • Epilepsy
      • Parkinson's Disease
      • Migraine
    • Cardiovascular Products
      • TABLE 14: LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013
    • Anti-arthritis Products
      • Steroids
      • NSAIDs
      • COX-II Inhibitors
      • DMARDs
        • TABLE 15: LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013
    • Respiratory Products
      • Asthma
      • COPD
      • Allergic Rhinitis
      • Bronchodilators
        • Inhaled bronchodilators
        • Anticholinergics
        • Oral bronchodilators
      • Leukotriene antagonists
      • Steroids
        • FIGURE 1: GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%)
        • TABLE 16: TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013
    • Anticancer Products
      • Cytotoxic Drugs
      • Hormonal Therapy
      • Biologic Response Modifiers
      • Antiangiogenesis Drugs
      • Monoclonal Antibodies
        • TABLE 17: LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013

CHAPTER 7 - THE GLOBAL GENERICS INDUSTRY

  • TABLE 18: TOP TEN GENERICS COMPANIES, 2012
  • TRENDS
  • STRUCTURE OF THE GENERICS INDUSTRY
  • RECENT M&A ACTIVITY
    • BRAND COMPANY INVOLVEMENTS

CHAPTER 8 - PROFILES OF TOP TEN GENERICS COMPANIES

  • ACTAVIS
  • APOTEX INC.
  • DR. REDDY'S LABORATORIES LTD.
    • ACQUISITIONS
    • FINANCIALS
  • HOSPIRA, INC.
    • BIOGENERICS
    • FINANCIALS
  • MYLAN INC.
    • FINANCIALS
    • LOOKING AHEAD
  • PAR PHARMACEUTICAL, INC.
    • GENERICS
    • FINANCIALS
  • RANBAXY LABORATORIES LIMITED
    • HISTORY
    • ACQUISITION BY DAIICHI SANKYO
    • FINANCIALS
    • LOOKING AHEAD
  • SANDOZ INTERNATIONAL GMBH
    • PRODUCTS
    • FINANCIALS
  • STADA ARZNEIMITTEL
    • GENERICS
    • BIOSIMILARS
    • FINANCIALS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • FINANCIALS
  • WATSON PHARMACEUTICALS INC.

CHAPTER 9 - OTHER INTERNATIONAL GENERICS COMPANIES

  • ASPEN PHARMACARE HOLDINGS LTD.
    • FINANCIAL RESULTS
  • AUROBINDO PHARMA LTD.
    • PRODUCTS
    • FINANCIALS
    • LOOKING AHEAD
  • BIOCON LTD.
  • CIPLA LTD.
    • FINANCIALS
  • COBALT PHARMACEUTICALS
  • EGIS PHARMACEUTICALS PLC
    • APIS
    • PHARMACEUTICAL R&D
    • FINANCIALS
  • GEDEON RICHTER PLC.
  • GENEPHARM GROUP
  • KRKA, D. D., NOVO MESTO
    • PRODUCTS
    • FINANCIALS
  • LUPIN LTD.
    • FINANCIALS
  • ORION CORPORATION
    • PRODUCTS
    • GENERICS
    • FINANCIALS
    • LOOKING AHEAD
  • PFIZER INC.
    • FINANCIALS
  • PLIVA D.D.
  • ROXANE LABORATORIES INC.
  • SANOFI
    • FINANCIALS
    • LOOKING AHEAD
  • SAWAI PHARMACEUTICAL
    • PRODUCTS
    • FINANCIALS
  • STRIDES ARCOLAB LIMITED
    • PRODUCT RANGE
    • LOOKING AHEAD
  • TANABE SEIYAKU HANBAI
  • WOCKHARDT LIMITED
    • FINANCIALS
  • ZYDUS CADILA
    • FINANCIALS

CHAPTER 10 - THE AMERICAN REGION

  • UNITED STATES
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
    • THE U.S. PHARMACEUTICAL MARKET
      • TABLE 19: U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • THE GENERIC MARKET: SIZE AND GROWTH
      • Biosimilars
      • Generic Prices
      • "Carve-Outs"
      • Generics Industry
        • FIGURE 2: U.S. PHARMACEUTICAL SHARES BY VALUE ($ PERCENT) AND PERCENTAGE SHARE OF PRESCRIPTIONS, 2012 (%)
      • The Future
  • CANADA
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
    • THE PHARMACEUTICAL MARKET
      • TABLE 20: CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • GENERICS
      • Generic Prices
        • TABLE 21: LEADING PHARMA COMPANIES IN CANADA, 2011
      • Future Market Growth
      • How Generics are Supplied
  • LATIN AMERICA
    • BRAZIL
      • Vital Statistics
      • Health and Healthcare
      • Pharmaceutical Market
        • TABLE 22: PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018 ($ BILLIONS/%)
      • Generic Market
      • M&A Activity
      • Background
      • ProGenericos
  • MEXICO
    • Vital Statistics
    • Health and Healthcare
    • Pharmaceutical Market
    • Generic Sector
      • TABLE 23: PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018 ($ BILLIONS/%)
    • Generic Industry
    • Regulatory Issues
  • AMEGI
    • Recent Developments

CHAPTER 11 - THE ASIAN REGION

  • JAPAN
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
    • PHARMACEUTICAL MARKET
      • TABLE 24: JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS/%)
      • TABLE 25: TOP FIVE JAPANESE PHARMA COMPANIES, 2012
      • Generic Sector
      • Foreign Presence
      • Market Resistance
      • Generics Industry
  • INDIA
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Growing Affluence - Changing Medical Needs
      • Regulatory Changes
    • PHARMACEUTICAL MARKET
      • Demographic Factors
        • TABLE 26: INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS/%)
      • Pharma Industry
      • Patent Reform
      • Generic Industry
        • TABLE 27: LEADING PHARMA COMPANIES IN INDIA, 2012
  • CHINA
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
    • PHARMACEUTICAL MARKET
      • TABLE 28: PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 ($ BILLIONS/%)
      • Domestic Industry
      • Foreign Company Involvement
      • Importance of R&D
      • Challenges
      • Market Trends
      • Regulatory Changes
      • Generic Exports
      • Domestic Generic Market
      • Local Dominance
        • FIGURE 3: GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%)

CHAPTER 12 - THE EUROPEAN REGION

  • FRANCE
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Healthcare Provision
        • FIGURE 4: HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS A PERCENTAGE OF GDP, 2007 (%)
    • PHARMACEUTICAL MARKET
      • TABLE 29: PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 ($ BILLIONS/%)
      • Generic Sector
  • GERMANY
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Provision of Healthcare
    • PHARMACEUTICAL MARKET
      • TABLE 30: LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY HEALTH INSURANCE SCHEME, 2011 ($ MILLIONS)
      • Price Controls
        • TABLE 31: PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018 ($ BILLIONS)
      • Generics Sector
  • ITALY
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Healthcare System
    • PHARMACEUTICAL MARKET
      • Implications for Research
        • TABLE 32: SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN
        • TABLE 33: PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 ($ BILLIONS/%)
      • Generics Sector
  • SPAIN
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Healthcare Provision
      • Pharmaceutical Services
    • PHARMACEUTICAL MARKET
      • TABLE 34: PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 ($ BILLIONS/%)
      • Generics Sector
      • Generics Industry
        • TABLE 35: LEADING GENERICS COMPANIES IN SPAIN, 2010
  • UNITED KINGDOM
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Healthcare Provision
        • Private Sector Involvement
        • Pharmaceuticals
    • THE PHARMACEUTICAL MARKET
      • TABLE 36: LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011
      • The Generic Sector
      • TABLE 37: PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM, THROUGH 2018 ($ BILLIONS/%)
  • RUSSIA
    • VITAL STATISTICS
    • HEALTH AND HEALTHCARE
      • Healthcare Delivery
    • PHARMACEUTICAL MARKET
      • ‘Pharma 2020'
        • TABLE 38: PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 ($ BILLIONS/%)
        • TABLE 39: LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012

LIST OF TABLES

  • SUMMARY TABLE: MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 ($ BILLIONS)
    • TABLE 1: GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION, THROUGH 2018 ($ BILLIONS)
    • TABLE 2: MAJOR PATENT EXPIRATIONS IN 2011 AND 2012
    • TABLE 3: MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE EXPIRIES
    • TABLE 4: BRAND SALES BEFORE AND AFTER PATENT EXPIRY ($ BILLIONS)
    • TABLE 5: BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN 2013 (SALES IN U.S. DOLLARS FOR Q1 2013)
    • TABLE 6: BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006
    • TABLE 7: EU APPROVED BIOSIMILAR APPLICATIONS, 2012
    • TABLE 8: REQUIREMENTS FOR NDA AND ANDA APPLICATIONS
    • TABLE 9: WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS)
    • TABLE 10: CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2018 ($ BILLIONS)
    • TABLE 11: TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 ($ BILLIONS)
    • TABLE 12: LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013.
    • TABLE 13: LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013
    • TABLE 14: LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013
    • TABLE 15: LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013
    • TABLE 16: TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013
    • TABLE 17: LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013
    • TABLE 18: TOP TEN GENERICS COMPANIES, 2012
    • TABLE 19: U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 20: CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 21: LEADING PHARMA COMPANIES IN CANADA, 2011
    • TABLE 22: PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 23: PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 24: JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 25: TOP FIVE JAPANESE PHARMA COMPANIES, 2012
    • TABLE 26: INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 27: LEADING PHARMA COMPANIES IN INDIA, 2012
    • TABLE 28: PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 29: PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 30: LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY HEALTH INSURANCE SCHEME, 2011 ($ MILLIONS)
    • TABLE 31: PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018 ($ BILLIONS)
    • TABLE 32: SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN 195
    • TABLE 33: PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 34: PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 35: LEADING GENERICS COMPANIES IN SPAIN, 2010
    • TABLE 36: LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011
    • TABLE 37: PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 38: PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 ($ BILLIONS/%)
    • TABLE 39: LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012

LIST OF FIGURES

  • SUMMARY FIGURE: MAJOR NATIONAL GENERIC MARKETS, 2012-2018 ($ BILLIONS)
    • FIGURE 1: GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%)
    • FIGURE 2: U.S. PHARMACEUTICAL SHARES BY VALUE ($ PERCENT) AND PERCENTAGE SHARE OF PRESCRIPTIONS, 2012 (%)
    • FIGURE 3: GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%)
    • FIGURE 4: HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS A PERCENTAGE OF GDP, 2007 (%)
Back to Top